

**LONDON
STOCK
EXCHANGE**

An LSEG Business

NS Miscellaneous

APPOINTMENT TO DEVELOPMENT TEAM

[HELLENIC DYNAMICS PLC](#)

Released 07:00:05 26 January 2023

RNS Number : 8951N
Hellenic Dynamics PLC
26 January 2023

26 January 2023

Hellenic Dynamics plc
(*"Hellenic Dynamics" or the "Company"*)

Appointment of Carl Haffner to Medical Cannabis Cultivation Team

London, 26 January 2023: Hellenic Dynamics plc (LSE: HELD) is pleased to announce the appointment of Carl Haffner as part of Hellenic Dynamics' development team. Carl is an industry expert having been the Co-founder and Chief Operations Officer of UK firm Avida Global Ltd and Chief Executive Officer of Colombian based Avida Global SAS, a vertically integrated cannabis business.

Starting from a greenfield site, Avida Global went on to create a large-scale medical cannabis cultivation and extraction facility in Colombia achieving all necessary certifications including ISO, GACP & EU-GMP.

Carl left Avida Global in September 2022 and has remained active in the industry as a medical cannabis consultant.

Hellenic Dynamics is a medical cannabis cultivator specifically focused on the cultivation and supply of tetrahydrocannabinol ("THC") dominant strains of medical cannabis flowers destined for the rapidly growing medical cannabis markets across Europe. In December 2022, Hellenic Dynamics became the first medical cannabis cultivator to list on the London Stock Exchange's main market for listed securities.

Davinder Rai, CEO of Hellenic Dynamics, commented:

"As a seasoned medical cannabis industry expert I am delighted that Carl has joined our team. Having previously successfully established an EU-GMP cultivation facility, his appointment will provide additional support to ensure our targets are met."

Carl Haffner, commented:

"I am delighted to become part of the Hellenic Dynamics team and am excited by the prospects of establishing, in Greece, what could become one of Europe's leading large-scale medical cannabis cultivation facilities."

The Directors of the Company accept responsibility for the content of this announcement.

Enquires:

Hellenic Dynamics plc	+44 (0)20 3818 7850
Davinder Rai	davinder@hellenicdynamics.com

Cairn Financial Advisers LLP

Emily Staples / Jo Turner +44 (0)20 7213 0880

Peterhouse Capital
Lucy Williams / Charles Goodfellow +44 (0)20 7469 0930

J&H Communications
George Hudson +44 (0)7803 603130

About Hellenic Dynamics plc

Founded in 2019, Hellenic Dynamics is specifically focused on the cultivation and supply of THC ("tetrahydrocannabinol") - dominant strains of medical cannabis flowers, destined for the growing medical cannabis markets across Europe. Hellenic Dynamics' core strategy is to develop and operate its 40,000 square metre active cultivation licence from its 195,506 square metre facility located near Thessaloniki in Northern Greece. In full production, Hellenic Dynamics is capable of producing over 54,000 kg of dried flowers per annum.

Hellenic Dynamics will take advantage of its relatively low cost base resulting from a comparatively low cost of power, having its own running water supply and the labour rates for skilled and semi-skilled labour in Northern Greece.

25 European countries now allow medical cannabis via prescription and the European cannabis market is expected to reach €43.3 billion per annum by 2027. Sales of Hellenic Dynamics' dried THC-dominant cannabis flowers and extracts are initially intended for export into Europe's largest market - Germany, in addition to other European markets including domestically in Greece.

As the first medical cannabis cultivator to obtain a listing on the main market for listed securities of the London Stock Exchange, Hellenic is significantly different to the number of CBD (Cannabidiol) related companies that have appeared over the recent years. Hellenic Dynamics cultivates THC-dominant medical cannabis flowers. THC-dominant medical cannabis products are only available via a medical prescription. Medicinal cannabis has been approved for use both in the United Kingdom and Germany, plus 23 other European countries, for conditions including but not limited to chronic pain, intractable chemotherapy-related nausea, anxiety, insomnia, Tourette's syndrome, substance use disorder, multiple sclerosis, IBS, spinal cord treatment, lack of appetite due to HIV/AIDS, cachexia, anorexia and glaucoma.

For further information please visit our website www.hellenicdynamics.com

Caution regarding forward looking statements

Certain statements in this announcement, are, or may be deemed to be, forward looking statements. Forward looking statements are identified by their use of terms and phrases such as "believe", "could", "should" "envisage", "estimate", "intend", "may", "plan", "potentially", "expect", "will" or the negative of those, variations or comparable expressions, including references to assumptions. These forward-looking statements are not based on historical facts but rather on the Directors' current expectations and assumptions regarding the Company's future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward looking statements reflect the Directors' current beliefs and assumptions and are based on information currently available to the Directors.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

MSCPPUAGGUPWPUA

London Stock Exchange plc is not responsible for and does not check content on this Website. Website users are responsible for checking content. Any news item (including any prospectus) which is addressed solely to the persons and countries specified therein should not be relied upon other than by such persons and/or outside the specified countries. [Terms and conditions](#), including restrictions on use and distribution apply.

© 2023 London Stock Exchange plc. All rights reserved.